🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Galderma R&D clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and China registers with Galderma R&D as lead sponsor. Synced 26 Sep 2026
14Current trials
7Recruiting now
1Drug in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Galderma R&D is the lead sponsor of 14 current clinical trials in our USA, UK and China registers. 7 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Nemolizumab. The most-studied condition is Prurigo Nodularis.

ClinicalTrials.gov trials by status

  • Recruiting750%
  • Not yet open17%
  • Active, closed643%

Trials by phase

  • Not applicable643%
  • Phase 3321%
  • Phase 2321%
  • Observational214%
01

Clinical trials sponsored by Galderma R&D

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605 · Atopic Dermatitis
Observational Recruiting 2025-07 UK, USA
A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages
NCT07342400 · Cheek Wrinkles, Menopausal Women
Not applicable Recruiting 2025-08 USA
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
NCT07660835 · ClinicalTrials.gov ↗ · Moderate-to-Severe Atopic Dermatitis
Phase 2 Recruiting 2026-07 USA
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286 · ClinicalTrials.gov ↗ · Chin Augmentation
Not applicable Recruiting 2026-06 USA
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690 · ClinicalTrials.gov ↗ · Systemic Sclerosis
Phase 2 Recruiting 2026-02 USA
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618 · ClinicalTrials.gov ↗ · Prurigo Nodularis
Observational Recruiting 2025-08 USA
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
NCT07399028 · ClinicalTrials.gov ↗ · Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin
Not applicable Recruiting 2025-10 USA
A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition
NCT07805512 · ClinicalTrials.gov ↗ · Jawline Definition
Not applicable Not yet open 2026-09 China
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04204616 · ClinicalTrials.gov ↗ · Prurigo Nodularis
Phase 3 Active, closed 2021-01 UK, USA
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206 · ClinicalTrials.gov ↗ · Moderate-to-Severe Atopic Dermatitis
Phase 3 Active, closed 2019-12 UK, USA
Study to Evaluate the Safety and Effectiveness of GP0116
NCT05987163 · Skin Manifestations
Not applicable Active, closed 2023-04 USA
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977 · ClinicalTrials.gov ↗ · Chronic Pruritus of Unknown Origin
Phase 2 Active, closed 2025-10 USA
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
NCT07186413 · ClinicalTrials.gov ↗ · Acne Vulgaris
Phase 3 Active, closed 2025-09 China
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
NCT07047638 · ClinicalTrials.gov ↗ · Skin Quality Improvement
Not applicable Active, closed 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Galderma R&D trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Galderma R&D trials

15 conditions
Prurigo Nodularis2Moderate-to-Severe Atopic Dermatitis2Atopic Dermatitis1Skin Manifestations1Cheek Wrinkles1Menopausal Women1Chronic Pruritus of Unknown Origin1Chin Augmentation1Systemic Sclerosis1Volume Deficiency in the Mid-Face1Skin Laxity1Photo-aged Skin1Acne Vulgaris1Skin Quality Improvement1Jawline Definition1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA117
Clinical trials in UK31
Clinical trials in China30

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Prurigo Nodularis

SponsorTrials
Shanghai Mabgeek Biotech.Co.Ltd1

Sponsors with the most current trials registered for this condition.

06

Questions about Galderma R&D trials

How many clinical trials does Galderma R&D sponsor?

Galderma R&D is the lead sponsor of 14 current trials on ClinicalTrials.gov in our USA, UK and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Galderma R&D trials recruiting?

Yes. 7 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Galderma R&D testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Nemolizumab (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.